Sign in
4

Changes in Ownership

Keros Therapeutics, Inc. Filed Acc 0001209191-22-023037

Chief Operating Officer sold 864 shares at an average $57.49 ($49,675)

  • Chief Operating Officer acquired 864 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Rovaldi Christopher Chief Operating Officer 2022-04-01 Option exercise +864 $16.00 $13,824 864 D: show line 1 in the form
Rovaldi Christopher Chief Operating Officer 2022-04-01 Sale −2 $54.34 $109 862 D: show line 2 in the form
Rovaldi Christopher Chief Operating Officer 2022-04-01 Sale −104 $56.20 $5,845 758 D: show line 3 in the form
Rovaldi Christopher Chief Operating Officer 2022-04-01 Sale −287 $56.89 $16,327 471 D: show line 4 in the form
Rovaldi Christopher Chief Operating Officer 2022-04-01 Sale −366 $57.97 $21,217 105 D: show line 5 in the form
Rovaldi Christopher Chief Operating Officer 2022-04-01 Sale −105 $58.83 $6,177 0 D: show line 6 in the form
Open-market sales · 864 sh · avg $57.49 · $49,675

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Rovaldi Christopher Chief Operating Officer 2022-04-01 Option exercise · Employee Stock Option (right to buy) −864 9,730 D: show line 7 in the form
Loading xslF345X03/doc4.xml…